Is NCT06548490 recruiting in Harrisburg, PA?

Yes, NCT06548490 is currently recruiting participants at its Harrisburg, PA location. This opioid use disorder clinical trial is actively enrolling qualified participants.

How do I join the opioid use disorder clinical trial in Harrisburg?

To join this clinical trial in Harrisburg, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Harrisburg clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Opioid Use Disorder Clinical Trial in Harrisburg, PA

About This Opioid Use Disorder Study in Harrisburg

The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids? The investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semagl

Sponsor: Milton S. Hershey Medical Center

Who Can Participate

Inclusion Criteria

Age 18 to 75 years.

Body mass index (BMI) \> 18.

Able and willing to provide informed consent prior to any study-related activities.

Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \> 3 ("moderate" or "severe" in the "Specify If" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates).

Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and/or at an associated clinic at the time of enrollment.

Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone.

Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone.

If capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or or to abstain from sexual activity that could result in pregnancy (if applicable) while in the study.

Able to read and communicate in English to the level required to accept standard care and complete all study requirements.

Able and willing to engage/adhere to the entirety of the study protocol (19 weeks).

Not currently a prisoner.

Exclusion Criteria

Age \< 18 or \> 75 years.

Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.

Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.

History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.

Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule.

Type 1 diabetes or history of diabetic ketoacidosis.

Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide.

Hypoglycemia on intake visit (blood glucose \< 60 mg/dL).

End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \<30 mL/min per 1.73 square meters or previous renal transplant.

End stage liver disease or previous liver transplant.

Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease.

Current or past diagnosis of gallbladder disease or gallstones.

Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke).

Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and/or history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and/or physician. As there is no specific scale that determines this, this will include the Site PI/physician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location.

Significant risk of suicide requiring a different/higher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and/or judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide.

Treatment with any investigational drug in the one month preceding the study.

Any contraindication to both methadone and BUP.

Any contraindication to a GLP-1R agonist.

Previous randomization for participation in this trial.

Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician.

Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study.

Currently a prisoner.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Harrisburg?

Yes, this clinical trial (NCT06548490) has an active research site in Harrisburg, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Opioid Use Disorder Treatment Options in Harrisburg, PA

If you're searching for opioid use disorder treatment options in Harrisburg, PA, this clinical trial (NCT06548490) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Harrisburg research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced opioid use disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all opioid use disorder clinical trials near you to find additional studies recruiting in your area.

Opioid Use Disorder Clinical Trial in Harrisburg, PA

Expert Care in Harrisburg

IRB Approved

No-Cost Care

Apply for This Harrisburg Location

Why Participate?

Simple Process